<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178135</url>
  </required_header>
  <id_info>
    <org_study_id>P2019005</org_study_id>
    <nct_id>NCT04178135</nct_id>
  </id_info>
  <brief_title>Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response</brief_title>
  <official_title>Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, controlled, pilot study, for Patients ≥ 35 years and &lt; 40 years old with&#xD;
      sufficient ovarian reserve parameters (AFC≥ 5), but showed an unexpected poor or suboptimal&#xD;
      ovarian response(defined as ≤ 9 retrieved oocytes in previous full-stimulation cycle, but not&#xD;
      get live birth after all embryos were used ). In order to get better oocyte number and&#xD;
      quality in the new COS cycle, we will compare LH supplementation from beginning with from&#xD;
      middle of stimulation in GnRH-a long protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 25, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of gestational sacs</measure>
    <time_frame>Day 28 after embryo transfer</time_frame>
    <description>Number of gestation sac will be detected by ultrasonographic visualization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility,Female</condition>
  <arm_group>
    <arm_group_label>rLH supplementation from day 1 of stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rLH supplementation from day 1 of stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rLH supplementation from day 6 of stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rLH supplementation from day 6 of stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rLH</intervention_name>
    <description>rLH supplement from day 1 of stimulation</description>
    <arm_group_label>rLH supplementation from day 1 of stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rLH</intervention_name>
    <description>rLH supplement from day 6 of stimulation</description>
    <arm_group_label>rLH supplementation from day 6 of stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Infertile women, 35≤ Age&lt; 40 years 2.18&lt;BMI&lt;28 Kg/m2 3.5 ≤AFC ≤20 4.Basal serum FSH≤10&#xD;
        IU/L, E2&lt;70 pg/ml 5.Previous cycle as the first COS cycle,AFC ≥ 5,starting dose of FSH&#xD;
        between 150 IU and 300IU with the possibility of adding r-hLH or hMG later in the cycle,&#xD;
        number of oocytes retrieved ≤9 (4-9 oocytes retrieval as suboptimal responder and &lt;4&#xD;
        oocytes retrieval as unexpected poor responder), but not get live birth after all embryos&#xD;
        were used.&#xD;
&#xD;
        6.Normal uterus and at least one side of the normal ovary 7.GnRH-a long protocol, using&#xD;
        Gonal-F® 300IU and Luveris® 150IU for COS 8.Informed consent form signed 9.Willing to&#xD;
        follow the study protocol, and able to complete this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Moderate and Severe endometriosis&#xD;
&#xD;
          2. PCOS&#xD;
&#xD;
          3. Previous ovarian surgery history&#xD;
&#xD;
          4. History of recurrent miscarriages (&gt;2 times of miscarriages)&#xD;
&#xD;
          5. Any major systemic disease that as per Investigator's discretion precludes subject for&#xD;
             participation in the study&#xD;
&#xD;
          6. With pregnancy contraindications Alcoholism, drug abuse, drug addiction or patients&#xD;
             with uncured sexually transmitted disease&#xD;
&#xD;
          7. According to the judgment of the Investigator, any medical condition or any&#xD;
             concomitant surgery/medications that would interfere with evaluation of study&#xD;
             medications&#xD;
&#xD;
          8. Simultaneous participation in another clinical study&#xD;
&#xD;
          9. Plan to use other Gn other than Gonal-F® or Luveris® during COS treatment Thyroid&#xD;
             gland disorders&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Months</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sufen Cai, Doctor</last_name>
    <phone>0731-82355100</phone>
    <email>ajiu0305@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of CITIC-XIANGYA</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sufen Cai, doctor</last_name>
      <phone>0731-82355100</phone>
      <email>ajiu0305@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>poor or suboptimal ovarian response,GnRH agonist long protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

